Dry Age-Related Macular Degeneration AMD Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The dry age-related macular degeneration market is expected to grow at a CAGR of 8.47% from 2024 to 2032, reaching a total market size of $ 4.8 billion in 2024. The annual growth rate of this market will be strong, at 8.3 percent from 2023 to 2032, indicating a strong demand for new treatments and an increased awareness of the aging population. As the prevalence of age-related eye diseases increases, driven by the population and the lifestyle, the market will see significant advances in the development of treatment and diagnostic solutions. The emergence of new therapies and the increasing prevalence of dry AMD will contribute to the growth of this market. The main market players, such as Regeneron, Novartis, and Roche, are focusing on clinical trials and product launches to improve treatment outcomes and patient outcomes. Strategic alliances, such as between pharmaceutical companies and research institutions, are also driving innovation in the field. These initiatives not only seek to address the unmet medical needs, but also seek to capture the growing market potential, thus driving the overall growth of the dry AMD market.

Regional Market Size

Regional Deep Dive

The dry age-related macular degeneration (AMD) market is characterized by a growing aging population and the increasing awareness of eye health across various regions. In North America, Europe, and parts of Asia-Pacific, the prevalence of dry AMD is on the rise due to the lifestyle of the population and the increasing life expectancy. The market dynamics are influenced by the introduction of new therapies and diagnostic tools, and the high investment in research and development by the leading companies. The regulatory framework in these regions is evolving to facilitate the faster approval of new treatments, which will further fuel the market growth.

Europe

• The European Medicines Agency (EMA) has streamlined its approval process for innovative AMD treatments, encouraging pharmaceutical companies to invest in research and development within the region.
• Collaborations between leading universities and biotech firms, such as the partnership between the University of Oxford and several startups, are fostering innovation in AMD therapies, potentially leading to breakthrough treatments.

Asia Pacific

• Countries like Japan and South Korea are witnessing a surge in clinical trials for new AMD therapies, with local companies like Santen Pharmaceutical leading the charge in developing novel treatment options.
• Government initiatives in Australia, such as the National Eye Health Plan, are focusing on improving access to eye care services, which is expected to enhance early diagnosis and treatment of dry AMD.

Latin America

• Brazil is seeing an increase in partnerships between public health organizations and private companies to enhance AMD awareness and treatment accessibility, which is vital in a region with limited healthcare resources.
• Regulatory bodies in Latin America are beginning to adopt more stringent guidelines for the approval of AMD treatments, which may lead to improved safety and efficacy standards in the market.

North America

• The FDA has recently approved several new therapies for dry AMD, including gene therapies and anti-VEGF treatments, which are expected to significantly improve patient outcomes and drive market growth.
• Organizations like the American Academy of Ophthalmology are actively promoting awareness campaigns about the importance of early detection and management of AMD, which is likely to increase patient engagement and treatment adherence.

Middle East And Africa

• In the UAE, the government has launched initiatives to improve eye health awareness, which is crucial in a region where lifestyle diseases are prevalent and can contribute to AMD.
• The establishment of specialized eye care centers in countries like South Africa is improving access to AMD diagnosis and treatment, addressing a significant gap in healthcare services.

Did You Know?

“Approximately 85-90% of all age-related macular degeneration cases are classified as dry AMD, making it the most common form of the disease.” — American Academy of Ophthalmology

Segmental Market Size

Dry age-related macular degeneration is a significant part of the ophthalmic market, which is growing steadily as a result of an aging population and the growing importance of eye health. The growing prevalence of age-related eye diseases and technological progress in diagnostics have led to an increase in the detection and treatment of these diseases. In addition, regulatory policies promoting the development of ophthalmic drugs and devices are driving demand for new treatments and solutions. The current stage of the market for dry age-related macular degeneration treatments is in the expansion phase, with Genentech and Regeneron leading the way in developing effective therapies. The most advanced regions, North America and Europe, are leading the way in their uptake, supported by their strong healthcare systems. Anti-VEGF therapies and nutritional supplements are the most commonly used treatments. The emergence of trends such as the increasing importance of individualized medicine and telehealth services is driving the growth of the market, while technological advances such as the use of artificial intelligence in diagnostics and medical imaging are shaping its future development.

Future Outlook

The market for dry AMD is expected to grow significantly from 2024 to 2032. The value of the market is projected to increase from $ 4,858 million to $ 8,611 million, with a CAGR of 8.3 percent. This is mainly due to the aging of the population, as the prevalence of dry AMD is expected to rise with the increasing number of people over 65. By 2032, it is expected that nearly 20 percent of this population will have some form of age-related visual impairment, which will increase the potential patient population and thus drive the demand for effective treatment. Also, there are major technological advances, especially in gene therapy and new pharmacological treatments, which are expected to revolutionize the treatment of dry AMD. Sustained-release drug delivery systems and the development of neuroprotective agents are expected to improve treatment efficacy and patient compliance. Awareness and early diagnosis, which will be facilitated by the development of diagnostics, will also increase the penetration of therapeutic interventions. Also, with the increasing emphasis on preventive care and the management of chronic diseases, the dry AMD market will benefit from greater support for research and development, which will further increase the growth potential in the coming years.